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Abstract Tremendous progress has been made in biomed-
ical research in genomics, proteomics and metabolomics,
which has led to an increasing insight into molecular
mechanisms related to diseases. Yet the output of disease
prevention, diagnosis and treatment solutions remains low.
It is against this background that several European
countries have gathered to take new actions for improving
translational research from bench to bedside. Surveys were
conducted to identify major bottlenecks and assess the
situation of translational research in Europe. While the
importance of translational research is already recognized
and national governments have increased their efforts and
academia more and more directs its research towards
translation, there are still hurdles to overcome. Thus, a
European research infrastructure—EATRIS—will be estab-
lished to integrate basic and clinical research in dedicated
translational centres. These EATRIS Centres will provide
broad access to high-end pre-clinical and clinical facilities,
including the necessary translational expertise for research-
ers from academia and industry.
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Introduction
Biological and biomedical research has witnessed a
significant acceleration of discoveries and data gathering.
Analyses at molecular level, genomics, proteomics and
metabolomics, as well as the growing use of high-
throughput technologies, have led to an exponential
increase in information about the underlying mechanisms
of diseases. However, contrary to expectations of early
genome research, this has not been materialized by an
increase in the output of new therapies or diagnostics.
Especially within academic research, there is a huge gap
with respect to the process of transferring research findings
from applied basic research to clinical practice. This gap
has been recognized, and within the last decade, the area of
translational research has gained much attention.
At the same time, the pharmaceutical industry is facing
worrying challenges in seeking novel means of extracting
value in the R&D process, due in part to dwindling drug
pipelines and the looming patent cliff that many firms
face. The current drug testing strategy of the industry
involves testing early for safety and toxicity and then
later testing for efficacy. This strategy often leads to vast
sums of money being spent on testing, only to discover
later that the drug is not efficacious. In fact, for every ten
drugs that enter clinical testing, only one will make it to
market. This is a contributory factor to a R&D process
that ends up with a required developmental period up to
15 years and an average price tag of Euro 1.5 billion per
novel drug brought to market. Furthermore, despite
doubling of R&D expenditures by pharma industry, the
output of new molecular entities (NME) in Europe has
halved between 1989 and 2008 [1]. However, the real
innovation crisis for patients and society is not the recent
decline in NME, but the small percentage that provide
R. Becker (*)
EATRIS Project Management,
Helmholtz Centre for Infection Research (HZI),
Inhoffenstr. 7, 38124 Braunschweig, Germany
e-mail: eatris@helmholtz-hzi.de
G. A. M. S. van Dongen
Departments of Otolaryngology/Head and Neck Surgery and
Nuclear Medicine and PET Research,
VU University Medical Center,
Amsterdam, The Netherlands
J. of Cardiovasc. Trans. Res. (2011) 4:231–237
DOI 10.1007/s12265-011-9260-8
distinguished clinical advantages to patients over existing
medications. In 2005, all of the top ten best-selling drugs
on the market were “copycats”, drugs that hit precedented
targets and work by the same mechanism of action as
other approved drugs [2]. Thus, the pharmaceutical R&D
pipeline is in serious need of making drug development
and testing more efficient and effective, as well as finding
new innovative targets that meet real medical needs.
Academic labs that are doing basic science and are
interested in applying their discoveries to drug discovery
are predestinated to find cures for diseases with high
unmet medical needs by focusing on innovative targets
and therapeutics.
Academic Research as an Important Basis for Novel
Drugs
Most important biopharmaceutical innovations have orig-
inated from ideas and discoveries in universities and
basic research centres, and the academia is more and
more interested in applying their research findings to
drug discovery [3, 4]. But advancing ideas on the
developmental path from basic research observations to
clinical applications is often hampered within academia.
Some common bottlenecks lay in the culture of biomed-
ical research itself. There is a lack of exchange between
the different disciplines, e.g. mostly a physical separation
exists between clinical and basic research. Publication and
citation, rather than patents, are highly valued. Nonethe-
less, activities of universities and public research centres
in drug discoveries are increasing, despite facing many
challenges. It is against this background that several
European countries have gathered to take concerted new
actions for improving translational research from bench to
bedside. They have identified centres of excellence in
translational biomedical research to create EATRIS, the
European Advanced Translational Research Infrastructure
in Medicine. EATRIS is one of the biomedical projects
initiated by the European Strategy Forum on Research
Infrastructure initially funded by the 7th Framework
Programme of the European Union. FP7 lays emphasis
on translating research for human health to maintain
Europe’s competitiveness in biomedical research and in
health industry.
Status of Translational Research in Europe
To establish such a pan-European research infrastructure, it
is important to have a clear view of the actual situation in
translational research. Thus, EATRIS conducted a survey in
which 54 academic non-profit institutions from 14 countries
participated.1 Almost half of the questioned translation
centres (46%) have only been implemented since the year
2000, which mirrors the growing awareness of the
importance of translational research in recent years. The
centres rely mainly on national funding and thus, on the
national economy, followed by industry and EU funding.
Cancer is the most prominent research field of the surveyed
translation centres, followed by cardiovascular diseases,
neurological disorders and infectious or metabolic diseases.
This probably reflects the structure of research funding and
the priorities of national programmes. Medicinal product
types which seem to be highly relevant are diagnostics and
prognostic markers, while therapeutic approaches are
slightly less frequent (cell therapies 69%, drug development
65%, biopharmaceuticals 42%, biomaterials/bioengineering
35%). The prevalence of diagnostics and prognostic
markers might be due to different procedures for market
approval, as the approval process is less complex and
expensive.
Half of the translational centres use institutionalised
collaborations to complement their translational infrastruc-
ture. The clinical facilities belonging to the translation
centres vary widely in size, but most centres have access to
clinics.
Besides the proximity of research and clinic, it was stated
that specialisation in a specific research area (or specialisation
of the research facility) together with good collaborations
between the translation centre and the clinic was seen as the
strongest asset of the translation centres. Despite the impor-
tance of focus, the centres pointed out that multidisciplinarity
are essential for successful translational research.
Developmental Stage and Output of the Translational
Centres
Considering the implementation dates of the centres and the
average time until a treatment is approved, it is not
surprising that the number of developmental candidates in
any clinical phase is remarkably low in all centres; the same
is true for commercialized patents, candidates licensed to
other companies or market-approved treatments.
When analysing good laboratory practice (GLP) data in
comparison to data acquired for the numbers of clinical phase
II/III trials, an interesting relation could be seen. While among
centres without GLP facilities only 7% have more than ten
candidates in phase II/III trials, 45% of centres with facilities
working under GLP conditions have more than ten candidates
1 The survey has been set up as structured telephone interviews to
guide the interviewees through the internet-based questionnaire and
provide the possibility to clarify questions about content, structure and
background of the survey.
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in phase II and III trials. Obviously, those centres which are
more tailored to handle regulatory requirements have a higher
output towards the clinic.
Challenges in Translational Research
Academia is the nucleus for the discovery of virtually all
new ideas or the identification of new targets. Conse-
quently the translational centres participating in the
survey showed a strong prevalence of equipment and
facilities that are needed for basic research. However,
also equipment related to clinical research is abundant
due to the proximity of research and clinical facilities.
Yet, to advance an idea to initial testing in humans,
further infrastructure or services are needed that are
usually not available within academia such as synthesiz-
ing active pharmaceutical ingredients, toxicological work,
safety data and regulatory requirements. The more
expensive and complex the equipment, the less it is
represented and the proportion of collaborations is larger.
Thus large chemical libraries are established only in very
few institutions, while most in an academic environment
access these in a collaborational model. Especially in the
area of imaging, it can be seen that very expensive
facilities like cyclotrons and hot labs for tracer produc-
tion according to good manufacturing practice (GMP)
and advanced instruments like PET-CT2 and Ultra-high-
field MRI3 are quite rare.
In most cases, academia lacks the access to facilities and
technologies, services and expertise necessary to advance
an idea towards pre-clinical and clinical phases. However,
not only translational infrastructure is limited but also
financial resources. Even the centres with a translational
focus identified finance as a bottleneck in translational
research. The traditional model of government support does
not meet the costs, diversity and complexity of translational
research.
Other topics unfamiliar to scientists are regulatory issues
or intellectual property. Most interviewees judged lack of
counselling and support for regulatory issues as a major
roadblock in translational research. Yet so far, less than half
of the translation centres employ regulatory affairs special-
ists at all. Many regulatory requirements affect the
development process already at a very early stage. It has
shown often in the past that a lack of awareness of
researchers about these requirements lead to unnecessarily
wasted time and money. It was expressed by the inter-
viewees that a help-desk service for regulatory issues,
which is open for academic researchers, would be desirable
and could avoid such failures.
The centres emphasize the necessity of a multidiscipli-
narity in translational research. To take full advantage of
this approach, basic researchers and clinicians must learn to
understand and communicate with each other [5]. Training
of clinical scientists in basic research and of basic
researchers in clinical aspects is seen as a key factor for
successful translational research. Especially as qualified
staff is regarded as another limitation due to the current
fragmentated nature of science.
Needs of Biomedical Researchers
In addition, the needs of the potential users of translational
research infrastructure (including universities, research
centres, research hospitals, SMEs—small and medium
enterprises—from several European countries4) have been
questioned in another survey.
In general, the results show that the needs for access to
research facilities and services depend largely on the
specific research activities of the research institutions, as
well as on their research environment. However, they also
underline the necessity to integrate basic and clinical
research. Academic researchers expressed a strong need
for patient-related offerings such as biobanks, access to
patient cohorts and clinical phase I/II facilities—usually not
available in academia. Additionally, specific pre-clinical
services such as access to libraries are requested.
It is surprising that apparently many research hospitals
do not yet have (sufficient) testing facilities for clinical
phase I trials nor the corresponding expertise. Accordingly,
they show an even higher interest in counselling in
regulatory and ethical issues and first-in-man phase I
clinical trials than the other research institutions.
SMEs also expressed their interest in access to patient
cohorts, but also to well-equipped and GLP laboratories
and clinical phase I facilities. Additionally, they would seek
support for the design of clinical phase I studies. It can be
seen that their interests are strongly focussed on forwarding
their development but they seem to be able to cover the IP-
relevant steps of the pre-clinical development already.
Conclusion
The surveys provided interesting insight into the status of
translational research in Europe. While the awareness of the
importance of translational research is already there and
2 PET (Positron Emission Tomography), CT (x-ray computed tomography)
3 MRI (Magnetic Resonance Imaging)
4 In total, 161 researchers from 28 countries participated in the
EATRIS survey conducted with an online questionnaire.
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novel centres are being built up, a lot of bottlenecks still
need to be overcome and processes have to be optimised.
Especially important goals which need to be achieved are:
– Provision of infrastructure and services
– Integration of basic research and clinic
– Counselling in regulatory issues and clinical phase
trials
– Substantiated funding concepts
– Concepts for training and education
A European infrastructure as envisioned by EATRIS
could be the ideal instrument to implement the relevant
actions all over Europe and to allow a faster and more
efficient translation of basic research findings into the
development of innovative diagnostics and medicinal
products.
The Concept of EATRIS: Opening the Doors
EATRIS is purposefully designed to help overcome the
challenges faced by researchers when translating results from
bench to bedside. This will be achieved by establishing a
research infrastructure of translational “EATRIS Centres”.
EATRIS will provide access to these centres, which comprise
both state-of-the-art expertise and the capital-intensive facil-
ities residing in Europe’s top translational research centres and
hospitals. This access is available through a collaboration
approach to academia worldwide. Additional financing
needed for the research and development projects is envisaged
through public and private funds.
The infrastructure will be established in existing research
institutions and clinics with proven track records in
translational research. To build an EATRIS Centre, leading
European research institutions dedicate part of their
research and development capacities to EATRIS. Clinics
and research centres integrate their working procedures for
translational research and development to create “virtual
centres”, covering the entire product development chain up
to the clinic (Fig. 1).
The goal is to have all necessary disciplines (basic and
clinical research) close together as a strong innovation core
(Fig. 2). The EATRIS translational research infrastructure
will overcome fragmentation by establishing multi-
disciplinary teams to accompany the projects run within
EATRIS. These teams bring together from the outset all
clinical, scientific, regulatory and product development-
related aspects needed over the course of the project. This
helps to ensure that all steps and potential issues during the
development process are considered from the start. Metic-
ulous quality control and continuous advancement of
facilities will ensure the necessary performance needed for
translation and successful transfer of EATRIS developmen-
tal candidates to industry.
According to their core expertise, the EATRIS Transla-
tion Centres will specialise in specific disease fields and on
the development of products such as diagnostics, small
molecular drugs, vaccines or advanced therapy medicinal
products (cell and gene therapy, tissue engineering). They
are complementary in their expertise and the portfolio of
research services. A central coordination and support office
in EATRIS serves as an access and information point and
will organise the routing of researchers to the most suitable
EATRIS Centre (Fig. 3).
Within the EATRIS Centre, the researchers can find the
necessary support and the facilities needed for translational
research as all disciplines around the development of
diagnostics and therapeutics, basic research and clinical
research are being made available. Access depends on the
innovation of their approach and the probability that the
research findings can actually lead to added value in
healthcare. An EATRIS Centre can take research findings
to a first proof-of-concept in human up to early clinical
phase IIa studies.
EATRIS benefits from the variety of expertise and high-
end technological platforms available in the different
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Fig. 1 The developmental chain
is the sequence of consecutive
R&D steps for product devel-
opment of clinical application in
diagnosis, therapy or prevention.
EATRIS will cover the steps
highlighted in blue and offer
translational support and conti-
nuity along the entire process
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participating centres. The different institutions can comple-
ment each other for a research project. In addition, common
standard operating procedures and harmonised data han-
dling will allow cross-validation of results and multi-centre
studies. Innovative approaches will be achieved through the
close cooperation of clinicians and scientists. The biolog-
ical and technological research taking place in parallel to
the translational activities lead to a cross-fertilisation and
thus enable cutting edge facilities available in the develop-
ment process. The technology platforms around molecular
imaging and biomarker development allow in this context
not only the development of new diagnostics but can be
used effectively to improve the developmental process as
described in the following section.
Molecular Imaging
Molecular imaging is a vital tool in biomedical research and
drug discovery. It can be used successfully to elucidate disease
mechanisms and identify new targets, contain development
costs, speed up the R&D process and increase pipeline output.
It provides substantial added value in several ways.
Molecular imaging and its concomitant area of tracer
development is becoming an essential tool for understand-
ing disease mechanisms by visualising and allowing
quantification of critical disease targets and molecules, be
it drug candidates or diagnostic agents [6, 7]. The use of
molecular imaging in evaluating the efficacy of new drugs,
testing early in the process (phase I/II) with small imaging-
enabled trials, allows the elimination of dead-end com-
pounds before vast multi-centre trial expenditures are made.
Dose–effect relations can be determined more accurately,
improving the quality and efficiency of studies and
reducing the risk of overdosing. The use of imaging in
such dose-finding studies can allow a reduction in the
number of volunteers needed in phase I by up to 80%.
Custom made tracers can be quickly developed in EATRIS
Tracer and Molecular Imaging Centres to support research-
ers and companies in testing of new drugs, generally with a
lead time of around 2 months or less.
Tracers can also become a unique tool in ATMP develop-
ment. Tracking of cells is vital to the efficiency of the approach.
EATRIS Centres can develop suitable “dyes” to mark the
respective cells or molecules to make them visible in vivo.
Furthermore, molecular imaging is important to stratify
patient cohorts, ensuring that the non-systemic risk of
failure from sampling errors is minimised. Imaging in
personalized medicine starts with disease delineation and
prognostication, followed by confirmation and quantifica-
tion of selective drug targeting, and finally, by early
response and outcome monitoring. All of this is possible
in patient cohorts displaying heterogeneous disease charac-
teristics, to identify the cohorts with the highest potential
for therapeutic benefit. One example is the use of positron
emission tomography (PET) in studying the in vivo
behaviour of therapeutic monoclonal antibodies (mAbs)
and their interaction with critical disease targets to assess
their efficacy early during treatment [7]. For expensive
therapeutics like mABs to which only some patients
respond, such characterisation of efficient use is vital to
make them affordable to society in the long run.
Within the EATRIS Tracer and Molecular Imaging
Centres, pre-clinical and clinical imaging facilities com-
prising PET, CT, SPECT, MRI/MRS, UltraSound, optical
imaging, as well as hybrid systems will be available under
the quality assurance and quality control conditions needed
for translational research. The corresponding radionuclide
production facilities and GMP labs, animal facilities,
Fig. 3 The EATRIS Translation Centres will specialise in specific
disease fields and on the development of products such as diagnostics,
small molecule drugs, vaccines or advanced therapy medicinal
products (cell and gene therapy, tissue engineering). They are
complementary in their specialisation and the portfolio of research
services. A central coordination office serves as an access and
information point and will organise the routing of researchers to the
most suitable EATRIS Centre
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Phase I Clinical 
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Fig. 2 In an EATRIS Centre, all necessary disciplines (basic and
clinic research) are close together as a strong innovation core. They
combine high-quality physical resources (so-called “bricks”) and
scientific expertise as well as professional project management
(“brains”). This “brick and brains” infrastructure will optimally guide
the scientist through the difficult process of translational medicine
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metabolite analysis and a clinical trial centre all form part of
the centres. EATRIS will not only make tracers available,
where needed, they can also give the necessary support to
researchers in the development of their tracers and the
necessary steps from laboratory to human.
Biomarkers
Biomarkers as quantifiable biological variables that character-
ise cellular, organ, physiological, pathological or clinical
conditions play a role in various steps of drug development.
Molecular diagnostics have become important means in risk
analysis and identification of a disease, as well as the
assessment of its severity. While many academic research
institutions engage in biomarker research, few are actually
validated and transferred to clinical use [8]. EATRIS wants to
dedicate its efforts in Biomarker Centres to improve
validation and will open its research facilities for external
researchers to support them in the validation process.
In addition, EATRIS Centres engage in biomarker
research in the context of drug development. Biomarkers
can be used in the early discovery stages of drug
development to validate the importance of the target in
human diseases as well as its “druggability”. They can also
be used to define the interaction of a compound with a
discrete target or to assess the pharmaco-kinetics of the
compound-target interaction.
The most important role of biomarkers is in the field of
personalised medicine. In diseases with high variability,
biomarkers are employed to identify patient subgroups to
allow specific therapy developments. Applied to patients
indiscriminately, drugs may not be judged to be effective
and thus be discarded, whereas it is may be highly effective
in the subgroup. It is also well-known that some patients
with certain molecular profiles react differently to their
medication. This does not only affect the efficacy, but also
the toxicity. Side effects up to serious adverse events can
depend crucially on the molecular profile of patients. For
this reason, the European Medicinal Agency (EMA) and
the Federal Drug Administration increasingly ask for
biomarker studies to accompany the development of new
therapies for the regulatory approval.
For biomarker validation and biomarker development for
patient stratification, the clinical link of EATRIS Centres is
most important. It is an essential element of all EATRIS
Centres that research hospitals and clinics are integrated
along with well-characterised patient cohorts and biobanks.
In addition, large-scale and automated screening facilities,
genotyping, proteomics and metabolomics facilities typify
EATRIS diagnostics centres, as well as libraries for
functional screens (cDNA, shRNA, siRNA, miRNA) or
antibody repositories.
Therapy Development
As mentioned above, EATRIS Centres specialise in different
therapies and diseases, where they integrate several different
institutions to cover the various disciplines needed and to
overcome fragmentation. Each institution will have a track
record in the research and development fields they cover in the
EATRIS Centre. Where needed, different EATRIS Centres
can complement each other for specialised activities (e.g.
specific animal models such as pigs or non-human primates).
Routine procedures such as formal pharmaco-kinetics and
pharmaco-dynamics studies for the regulatory approval
process can be bought as services from outside.
Research and development services for drug development
in EATRIS range from target confirmation to finding suitable
compounds and improving them to lead products in pre-
clinical and early clinical studies. Within EATRIS, compre-
The EATRIS consortium
Scientifi c Partners
  Atomic Agency Commission (CEA), France   
  Centre for Translational Molecular 
Medicine (CTMM), Netherlands 
  German Cancer Research Centre (DKFZ), 
Germany 
  Helmholtz Centre for Infection Research 
(HZI), Germany  
  Imperial College London, UK 
  Institute for Molecular Medicine Finland 
(FIMM), Finland 
  Istituto Superiore di Sanità (ISS), Italy
  Karolinska Institute (KI), Sweden 
  University Hospital Vall d‘Hebron 
(FIR-HUVH), Spain 
  University of Copenhagen, Cluster for 
Molecular Imaging (CMI), Denmark  
  University of Oslo (UiO), Norway
Governmental Partners
  Danish Agency for Science, Technology 
and Innovation (DASTI), Denmark  
  Federal Ministry of Education and 
Research (BMBF), Germany
 Helmholtz Association, Germany 
  Institute of Health Carlos III, Spain 
  Medical Research Council (MRC), UK 
  Ministry for Science and Culture of Lower 
Saxony (MWK), Germany  
  Ministry of Education, Finland
  Ministry of Labour, Health and Social 
Policies, Italy
  Stockholm County Council (SLL), Sweden  
  Swedish Research Council (SRC), Sweden
  The Netherlands Organisation of Health 
and Development (ZonMw), Netherlands 
  The Research Council of Norway, Norway
  Emerging Partner: Ministry for Development, 
Greece
Fig. 4 Ten European countries were involved in planning the EATRIS research infrastructure (turquoise)
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hensive molecule libraries are available. It is not intended to
compete with the pharmaceutical and biotech industry in this
field but to bridge the gap between academia and the private
sector. Better target confirmation with relevant animal models
and a clear characterization of targets will improve the uptake
by industry. Close interaction and open innovation collabora-
tion with industry is key, especially in this sector. In addition,
EATRIS can drive the research and development process
further to a proof of concept in human in the fields of, e.g.
orphan drugs where industry is reluctant to engage already in
the early stages of development.
In the so-called “Advanced Therapy Medicinal Products
(ATMP)” defined by the EMA to comprise cell and gene
therapies as well as regenerative medicine the focus of the
EATRIS support is on the specific needs in this field, namely
the support of academia in setting up delivery systems and
production processes which are amenable to scaling-up and
cGMP conditions, as well as the subsequent production. A
further service will be consultation and research about the best
way to comply with regulatory requirements. Innovative new
therapies in the ATMP field pose a challenge also to regulatory
authorities because the current rules were set up in the context
of drug development and do not transfer to the more complex
conditions such as those of cell therapies [9]. EATRIS
engages in these development fields and in research to find
new ways for the assessment of efficacy and safety in
advanced therapies. Support will be offered for all stages,
from the pre-clinical studies to the clinical phase IIa trials.
Outlook
After a three-year preparatory phase (2008–2010), which
had been funded by the European Commission, the
EATRIS consortium (Fig. 4) is about to implement the
planned pan-European translational infrastructure. A Mem-
orandum of Understanding was signed by ministries and
research councils in Finland, France, Germany, Italy,
Norway, Spain and The Netherlands, who want to follow
up EATRIS and create it as an independent legal entity.
New candidate countries will follow.
Some of the participating countries have already
launched calls to identify the institutions with the best
track records in translational medicine to build an EATRIS
Centres. This year, they will implement the EATRIS
Centres and already start first pilot projects to demonstrate
the operation of EATRIS. These activities will gradually be
transferred in the offer of support on a regular basis.
EATRIS will not be a static infrastructure but will evolve
following emerging new technological approaches and is
intended to react to emerging medical needs. Training
facilities and programs specifically dedicated to translation-
al research will also be developed and made available to the
research community. It is the aim of the participating
countries to improve the translational performance of their
own academic landscape and at the same time stimulate
translational research in general.
Summary: The Approach of EATRIS
& Creation of a pan-European consortium for translation
supporting researchers in conducting their biomedical
research, from discovery to proof-of-concept in human
in a lean and mean way
& Tackling fragmentation by integration of all disciplines
in comprehensive virtual centres and multi-disciplinary
management teams
& Engagement of specific knowledge and technology to
reduce risks in development
& EATRIS will be of special importance to researchers
without access to necessary translational infrastructure
and expertise. Through EATRIS, they will gain access
to translational centres with proven a track record.
& By offering an exchange platform to researchers in
academia and industry alike, EATRIS will encourage
closer collaboration.
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